Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.

Vivek SubbiahPete M AndersonKalevi KairemoKenneth HessWinston W HuhVinod RaviNajat C DawNeeta Somaiah Joseph A Ludwig Robert S BenjaminSant ChawlaDavid S HongFunda Meric-BernstamGregory RavizziniEugenie S KleinermanHomer MacapinlacEric Rohren

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

The first evaluation of the safety and efficacy of an alpha particle in high-risk osteosarcoma shows that the recommended phase II dose for 223RaCl2 in osteosarcoma is 100 kBq/kg monthly (twice the dose approved for prostate cancer), with minimal hematologic toxicity, setting the stage for combination therapies.

Keyphrases

phase ii
open label
prostate cancer
clinical trial
phase iii
radical prostatectomy
study protocol
oxidative stress
placebo controlled
drug administration